| 0.4059 -0.054 (-11.74%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.99 | 1-year : | 1.46 |
| Resists | First : | 0.85 | Second : | 1.25 |
| Pivot price | 0.49  |
|||
| Supports | First : | 0.2 | Second : | 0.17 |
| MAs | MA(5) : | 0.44  |
MA(20) : | 0.45 |
| MA(100) : | 0.7 |
MA(250) : | 2.26 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 20.5 |
D(3) : | 21.3 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 19.73 | Low : | 0.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AIM ] has closed above bottom band by 37.4%. Bollinger Bands are 67.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.44 | 0.44 - 0.44 |
| Low: | 0.36 - 0.36 | 0.36 - 0.37 |
| Close: | 0.4 - 0.41 | 0.41 - 0.41 |
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Thu, 11 Jun 2026
AIM ImmunoTech Prices $1.3 Million Registered Direct Offering; Adds $5.3 Million Warrant Upside - TradingView
Thu, 11 Jun 2026
AIM ImmunoTech (NYSE: AIM) prices $2.65M stock and warrant financing deal - Stock Titan
Wed, 10 Jun 2026
AIM ImmunoTech (AIM) shifts to majority-of-votes-cast rule for proposals - Stock Titan
Wed, 10 Jun 2026
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
Tue, 09 Jun 2026
AIM ImmunoTech announces $2.65M financing priced at market - MSN
Tue, 09 Jun 2026
AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|